Synthetic Curcumin Analog UBS109 Inhibits the Growth of Head and Neck Squamous Cell Carcinoma Xenografts

ISSN: 1873-5576 (Online)
ISSN: 1568-0096 (Print)

Volume 17, 9 Issues, 2017

Download PDF Flyer

Current Cancer Drug Targets

This journal supports open access

Aims & ScopeAbstracted/Indexed in

Ranking and Category:
  • 68th of 213 in Oncology

Submit Abstracts Online Submit Manuscripts Online

Ruiwen Zhang
Texas Tech University Health Sciences Center
1300 Coulter Drive
Amarillo, TX 79106

View Full Editorial Board

Subscribe Purchase Articles Order Reprints

Current: 3.707
5 - Year: 3.446

Synthetic Curcumin Analog UBS109 Inhibits the Growth of Head and Neck Squamous Cell Carcinoma Xenografts

Current Cancer Drug Targets, 14(4): 380-393.

Author(s): Shijun Zhu, Terry W. Moore, Nao Morii, Randy B. Howard, Richard F. Arrendale, Prabhakar Reddy, Taylor J. Evers, Hongzheng Zhang, Gabriel Sica, Zhuo G. Chen, Aiming Sun, Haian Fu, Fadlo R. Khuri, Dong M. Shin, James P. Snyder and Mamoru Shoji.

Affiliation: Department of Hematology and Medical Oncology, Winship Cancer Institute, Emory University, Atlanta, GA 30322, USA.


The natural compound curcumin has been investigated as an anticancer agent in many cellular systems, in animal models and in the clinic. The overriding negative characteristics of curcumin are its low solubility, weak potency and poor bioavailability. We have examined the efficacy and mechanism of action of a synthetic curcumin analog, UBS109, in head and neck squamous cell carcinoma. By nephelometry, this analog exhibits considerably greater solubility than curcumin. Pharmacokinetic studies of a single oral dose of UBS109 in mice revealed that peak plasma concentrations were reached at 0.5 hours post-dose (Tmax) with average plasma concentrations (Cmax) of 131 and 248 ng/mL for oral doses of 50 and 150 mg/kg, respectively. The terminal elimination half-lives (T½) for these doses averaged 3.7 and 4.5 hours, respectively. In both in vitro and in vivo studies, we found that UBS109 decreased the levels of phosphorylated IKKβ and phosphorylated p65 and, unexpectedly, increased the levels of phosphorylated IκBα by Western blot analysis. These observations may suggest that UBS109 suppresses tumor growth through, in part, inhibition of NF-κB p65 phosphorylation by PKAc and not through IκBα. Finally, we demonstrate that UBS109 is efficacious in retarding the growth of Tu212 (head and neck) squamous cell carcinoma (SCC) xenograft tumors in mice and may be useful for treating head and neck SCC tumors.


Head and neck squamous cell carcinoma xenografts, NF-κB p65 phosphorylation, pharmacokinetic and toxicologic studies, PKAc, solubility, synthetic curcumin analog UBS109.

Purchase Online Order Reprints Order Eprints Rights and Permissions

Article Details

Volume: 14
Issue Number: 4
First Page: 380
Last Page: 393
Page Count: 14
DOI: 10.2174/1568009614666140312163524
Price: $58
Orphan Drugs and Rare Diseases Europe 2017

Related Journals

Webmaster Contact: Copyright © 2016 Bentham Science